Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Murat Osman Arcasoy
Professor of Medicine
Medicine, Hematology
arcas001@mc.duke.edu
Duke Box 3912, Durham, NC 27710
Hosp South Trent Drive, Box 3912 DUMC, Durham, NC 27710
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
Professional Training and Employment
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: true}
Recognition
In the News
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A phase 1b Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF).
Clinical Trial
Principal Investigator ·
Awarded by Samus Therapeutics, Inc. ·
2018 - 2021
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects W/ Essential Thromboythemia Who Are Resistant to or Intolerant of
Clinical Trial
Principal Investigator ·
Awarded by Incyte Corporation ·
2017 - 2020
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2019
A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotimib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post essential Thrombocythemia Myelofibrosis
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2014 - 2019
Open-Label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Clinical Trial
Principal Investigator ·
Awarded by Gilead Sciences, Inc. ·
2016 - 2017
A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
Clinical Trial
Principal Investigator ·
Awarded by Janssen Research & Development, LLC ·
2016 - 2017
Erythropoietin Receptors in Breast Cancer
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2004 - 2010
Role of Erythropoietin Receptor Signaling in the Heart
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
2003 - 2006
Erythropoietin Receptor Regulation of Erythorpoiesis
Research
Principal Investigator ·
Awarded by National Institutes of Health ·
1998 - 2005
